The Safety of Tenofovir Disoproxil Fumarate Taken With Other Anti-HIV Drugs to Treat HIV-Infected Patients
Verified July 2001
Information provided by (Responsible Party)
NIH AIDS Clinical Trials Information Service
First received: December 19, 2000
Last updated: June 23, 2005
Last Verified: July 2001
History of Changes
The purpose of this study is to evaluate the safety of tenofovir disoproxil fumarate (tenofovir DF) in combination with other anti-HIV drugs in patients who have participated in other tenofovir DF studies (GS-98-902 or GS-99-907), are able to tolerate the drug at different doses, and may benefit from having tenofovir DF treatment.
Drug : Tenofovir disoproxil fumarate
Primary Purpose: Treatment
|Official Title:||A Phase 3, Open-Label, Multicenter Study of the Safety of Tenofovir Disoproxil Fumarate Administered in Combination With Other Antiretroviral Agents for the Treatment of HIV-1 Infected Patients|
Further study details as provided by NIH AIDS Clinical Trials Information Service:
Patients take tenofovir DF in combination with other antiretrovirals.Eligibility
|Ages Eligible for Study:||Child, Adult, Senior|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
Patients may be eligible for this study if they:
- Have completed another study on tenofovir DF without toxicity.
- Are willing to use intrauterine or effective barrier methods of birth control, both men and women, during the study and for 30 days following tenofovir DF treatment.
- Are taking drugs that may damage the kidney (nephrotoxic) including aminoglycoside antibiotics, amphotericin B, cidofovir, cisplatin, foscarnet, IV pentamidine, vancomycin, and oral or IV ganciclovir.
- Are taking agents that affect kidney function, such as probenecid.
- Are receiving systemic chemotherapy.
- Are taking systemic corticosteroids.
- Are taking experimental drugs except those that are approved by Gilead.
- Are currently participating in the GS-99-908 or GS-00-912 (expanded access) studies.
- Are pregnant or breast-feeding.
Patients will not be eligible for this study if they:
Contacts and LocationsChoosing to participate in a study is an important personal decision.Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00007436
Locations Show More
|United States, California|
|East Bay AIDS Ctr|
|Berkeley, California, United States, 94705|
|Tower ID Med Associates|
|Los Angeles, California, United States, 90048|
|Pacific Horizons Med Group|
|San Francisco, California, United States, 94115|
|Harbor - UCLA Med Ctr|
|Torrance, California, United States, 90502|
|United States, Colorado|
|Univ of Colorado / Health Science Ctr|
|Denver, Colorado, United States, 80262|
|United States, District of Columbia|
|Physicans Home Service|
|Washington, District of Columbia, United States, 20037|
|United States, Florida|
|Steinhart Medical Associates|
|Miami, Florida, United States, 33133|
|Dr Gerald Pierone Jr|
|Vero Beach, Florida, United States, 32960|
|United States, Illinois|
|Northstar Med Clinic|
|Chicago, Illinois, United States, 60657|
|United States, Massachusetts|
|CRI New England|
|Brookline, Massachusetts, United States, 02146|
|United States, Minnesota|
|Univ of Minnesota|
|Minneapolis, Minnesota, United States, 55455|
|United States, New York|
|Univ of Rochester Med Ctr|
|Rochester, New York, United States, 14642|
|United States, Oregon|
|Research & Education Group|
|Portland, Oregon, United States, 97209|
|United States, Pennsylvania|
|Hershey Med Ctr|
|Hershey, Pennsylvania, United States, 17033|
|Anderson Clinical Research|
|Pittsburgh, Pennsylvania, United States, 15221|
|United States, Rhode Island|
|Roger Williams Med Ctr|
|Providence, Rhode Island, United States, 02908|
|United States, Texas|
|Southwest Infectious Diseases Associates|
|Dallas, Texas, United States, 75246|
|Thomas Street Clinic|
|Houston, Texas, United States, 77009|
|United States, Washington|
|Dr Philip C Craven|
|Tacoma, Washington, United States, 98405|
Sponsors and CollaboratorsGilead Sciences
|Responsible Party:||Gilead Sciences|
|ClinicalTrials.gov Identifier:||NCT00007436 History of Changes|
|Other Study ID Numbers:||283F|
|Study First Received:||December 19, 2000|
|Last Updated:||June 23, 2005|
Keywords provided by NIH AIDS Clinical Trials Information Service:HIV-1
Drug Therapy, Combination
Reverse Transcriptase Inhibitors
Additional relevant MeSH terms:
ClinicalTrials.gov processed this data on July 20, 2018
This information is provided by ClinicalTrials.gov.